Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1998 Apr;57(4):209–213. doi: 10.1136/ard.57.4.209

HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments

J O'Dell 1, B Nepom 1, C Haire 1, V Gersuk 1, L Gaur 1, G Moore 1, W Drymalski 1, W Palmer 1, P Eckhoff 1, L Klassen 1, S Wees 1, G Thiele 1, G Nepom 1
PMCID: PMC1752573  PMID: 9709176

Abstract

OBJECTIVE—To determine the predictive value of shared epitope alleles for response to treatment in patients with rheumatoid arthritis.
METHODS—Patients from our previously published triple DMARD study were tested for the presence of shared epitope alleles (DRB1 *0401,0404/0408, 0405,0101, 1001,and 1402). Patients who were shared epitope positive were then compared with those who were negative to see if there was a differential effect on therapeutic response.
RESULTS—Shared epitope positive patients were much more likely to achieve a 50% response if treated with methotrexate-sulphasalazine-hydroxychloroquine compared with methotrexate alone (94% responders versus 32%, p<0.0001). In contrast shared epitope negative patients did equally well regardless of treatment (88% responders for methotrexate-sulphasalazine-hydroxychloroquine versus 83% for methotrexate). Additionally, a trend toward an inverse relation of the gene dose was seen for response to methotrexate treatment (p=0.05).
CONCLUSIONS—These data suggest that determining shared epitope status may provide clinical information useful in selecting among treatment options.

 Keywords: DRB1; rheumatoid arthritis; combination treatment; shared epitope

Full Text

The Full Text of this article is available as a PDF (199.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alarcón G. S., Blackburn W. D., Jr, Calvo A., Castañeda O. Evaluation of the American Rheumatism Association preliminary criteria for remission in rheumatoid arthritis: a prospective study. J Rheumatol. 1987 Feb;14(1):93–96. [PubMed] [Google Scholar]
  2. Combe B., Eliaou J. F., Daurès J. P., Meyer O., Clot J., Sany J. Prognostic factors in rheumatoid arthritis. Comparative study of two subsets of patients according to severity of articular damage. Br J Rheumatol. 1995 Jun;34(6):529–534. doi: 10.1093/rheumatology/34.6.529. [DOI] [PubMed] [Google Scholar]
  3. Emery P., Salmon M., Bradley H., Wordsworth P., Tunn E., Bacon P. A., Waring R. Genetically determined factors as predictors of radiological change in patients with early symmetrical arthritis. BMJ. 1992 Dec 5;305(6866):1387–1389. doi: 10.1136/bmj.305.6866.1387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Felson D. T., Anderson J. J., Meenan R. F. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum. 1990 Oct;33(10):1449–1461. doi: 10.1002/art.1780331001. [DOI] [PubMed] [Google Scholar]
  5. Felson D. T., Anderson J. J., Meenan R. F. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum. 1992 Oct;35(10):1117–1125. doi: 10.1002/art.1780351003. [DOI] [PubMed] [Google Scholar]
  6. Gregersen P. K., Silver J., Winchester R. J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987 Nov;30(11):1205–1213. doi: 10.1002/art.1780301102. [DOI] [PubMed] [Google Scholar]
  7. Kremer J. M., Lee J. K. A long-term prospective study of the use of methotrexate in rheumatoid arthritis. Update after a mean of fifty-three months. Arthritis Rheum. 1988 May;31(5):577–584. doi: 10.1002/art.1780310501. [DOI] [PubMed] [Google Scholar]
  8. Kremer J. M. The changing face of therapy for rheumatoid arthritis. Rheum Dis Clin North Am. 1995 Aug;21(3):845–852. [PubMed] [Google Scholar]
  9. Leech N. J., Kitabchi A. E., Gaur L. K., Hagopian W. A., Hansen J., Burghen G. A., Palmer J. P., Nepom G. T. Genetic and immunological markers of insulin dependent diabetes in Black Americans. Autoimmunity. 1995;22(1):27–32. doi: 10.3109/08916939508995296. [DOI] [PubMed] [Google Scholar]
  10. MacGregor A., Ollier W., Thomson W., Jawaheer D., Silman A. HLA-DRB1*0401/0404 genotype and rheumatoid arthritis: increased association in men, young age at onset, and disease severity. J Rheumatol. 1995 Jun;22(6):1032–1036. [PubMed] [Google Scholar]
  11. McMahon M. J., Hillarby M. C., Clarkson R. W., Hollis S., Grennan D. M. Major histocompatibility complex variants and articular disease severity in rheumatoid arthritis. Br J Rheumatol. 1993 Oct;32(10):899–902. doi: 10.1093/rheumatology/32.10.899. [DOI] [PubMed] [Google Scholar]
  12. McMichael A. J., Sasazuki T., McDevitt H. O., Payne R. O. Increased frequency of HLA-Cw3 and HLA-Dw4 in rheumatoid arthritis. Arthritis Rheum. 1977 Jun;20(5):1037–1042. doi: 10.1002/art.1780200501. [DOI] [PubMed] [Google Scholar]
  13. Morand E. F., McCloud P. I., Littlejohn G. O. Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice. J Rheumatol. 1992 May;19(5):704–708. [PubMed] [Google Scholar]
  14. Nepom G. T., Byers P., Seyfried C., Healey L. A., Wilske K. R., Stage D., Nepom B. S. HLA genes associated with rheumatoid arthritis. Identification of susceptibility alleles using specific oligonucleotide probes. Arthritis Rheum. 1989 Jan;32(1):15–21. doi: 10.1002/anr.1780320104. [DOI] [PubMed] [Google Scholar]
  15. Nepom G. T., Gersuk V., Nepom B. S. Prognostic implications of HLA genotyping in the early assessment of patients with rheumatoid arthritis. J Rheumatol Suppl. 1996 Mar;44:5–9. [PubMed] [Google Scholar]
  16. Nepom G. T., Nepom B. S. Prediction of susceptibility to rheumatoid arthritis by human leukocyte antigen genotyping. Rheum Dis Clin North Am. 1992 Nov;18(4):785–792. [PubMed] [Google Scholar]
  17. O'Dell J. R., Haire C. E., Erikson N., Drymalski W., Palmer W., Eckhoff P. J., Garwood V., Maloley P., Klassen L. W., Wees S. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med. 1996 May 16;334(20):1287–1291. doi: 10.1056/NEJM199605163342002. [DOI] [PubMed] [Google Scholar]
  18. Paulus H. E., Egger M. J., Ward J. R., Williams H. J. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. Arthritis Rheum. 1990 Apr;33(4):477–484. doi: 10.1002/art.1780330403. [DOI] [PubMed] [Google Scholar]
  19. Pincus T., Brooks R. H., Callahan L. F. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med. 1994 Jan 1;120(1):26–34. doi: 10.7326/0003-4819-120-1-199401010-00005. [DOI] [PubMed] [Google Scholar]
  20. Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med. 1978 Apr 20;298(16):869–871. doi: 10.1056/NEJM197804202981602. [DOI] [PubMed] [Google Scholar]
  21. Weyand C. M., Hicok K. C., Conn D. L., Goronzy J. J. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med. 1992 Nov 15;117(10):801–806. doi: 10.7326/0003-4819-117-10-801. [DOI] [PubMed] [Google Scholar]
  22. Winchester R., Dwyer E., Rose S. The genetic basis of rheumatoid arthritis. The shared epitope hypothesis. Rheum Dis Clin North Am. 1992 Nov;18(4):761–783. [PubMed] [Google Scholar]
  23. Wolfe F., Hawley D. J., Cathey M. A. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol. 1990 Aug;17(8):994–1002. [PubMed] [Google Scholar]
  24. Wolfe F., Hawley D. J. Remission in rheumatoid arthritis. J Rheumatol. 1985 Apr;12(2):245–252. [PubMed] [Google Scholar]
  25. Wolfe F., Mitchell D. M., Sibley J. T., Fries J. F., Bloch D. A., Williams C. A., Spitz P. W., Haga M., Kleinheksel S. M., Cathey M. A. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994 Apr;37(4):481–494. doi: 10.1002/art.1780370408. [DOI] [PubMed] [Google Scholar]
  26. Wordsworth B. P., Lanchbury J. S., Sakkas L. I., Welsh K. I., Panayi G. S., Bell J. I. HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. Proc Natl Acad Sci U S A. 1989 Dec;86(24):10049–10053. doi: 10.1073/pnas.86.24.10049. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Young A., Jaraquemada D., Awad J., Festenstein H., Corbett M., Hay F. C., Roitt I. M. Association of HLA-DR4/Dw4 and DR2/Dw2 with radiologic changes in a prospective study of patients with rheumatoid arthritis. Preferential relationship with HLA-Dw rather than HLA-DR specificities. Arthritis Rheum. 1984 Jan;27(1):20–25. doi: 10.1002/art.1780270104. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES